TrialCancer discovery2026

Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.

Salah-Eddine Bentebibel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.